Logo

Anixa Biosciences, Inc.

ANIX

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and d… read more

Healthcare

Biotechnology

42 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$3.41

Price

-0.29%

-$0.01

Market Cap

$116.019m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-33.3%

3y CAGR

-25.0%

5y CAGR
Earnings

-$10.074m

+7.8%

1y CAGR

-2.4%

3y CAGR

+5.2%

5y CAGR
EPS

-$0.30

+11.8%

1y CAGR

+0.9%

3y CAGR

+7.9%

5y CAGR
Book Value

$13.224m

$14.865m

Assets

$1.641m

Liabilities

$184k

Debt
Debt to Assets

1.2%

-

Debt to EBITDA
Free Cash Flow

-$7.117m

+0.8%

1y CAGR

-5.0%

3y CAGR

-2.7%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases